Latest news with #BTCY
Yahoo
5 days ago
- Business
- Yahoo
Biotricity Reinforces Growth Trajectory, Kicking Off Fiscal 2026 with Strong First Quarter Results Featuring Revenue Growth, Positive EBITDA and Improved Margins
REDWOOD CITY, CA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY) ("Biotricity" or the "Company'), an innovative Technology-as-a-Service (TaaS) company committed to redefining the landscape of the healthcare industry with state-of-the-art remote monitoring and diagnostic solutions, today announced its financial results for its first quarter of fiscal 2026, ended June 30, 2025. Dr. Waqaas Al-Siddiq, Biotricity Founder & CEO, said, "We're proud to deliver another quarter of strong performance and a shift to positive EBITDA, which demonstrates the scalability of our business model and strength of our team. Management believes that this a foundational milestone for Biotricity, exemplifying our ability to grow our business as we go from a loss-producing startup to a business that can operate profitably. Following a massive year of positive transformation for Biotricity, we continue to harness the power of workflow automation, AI technology, and other technological enhancements to further improve our operational expenses, margins, and revenues. This powerful combination has set the foundation to fuel ongoing growth. In doing so, we demonstrate our ability to scale with strategic focus and long-term sustainability. The expansion of our Cardiac AI Cloud platform, empowered by strategic partnerships with industry giants, showcases our commitment to revolutionizing medical diagnostics and consumer healthcare. Leveraging over 2 trillion beats of anonymized data, our AI-driven platform is set to enhance clinic profitability, paving the way for transformative advancements in diagnostic accuracy and patient outcomes. Importantly, we remain on track to pursue FDA clearance for our groundbreaking AI clinical model in the coming months. Strategic alliances forged during fiscal 2025 and 2026 have positioned us to capitalize on expansive market channels, providing access to approximately 90% of all hospitals in America and opening the door to managed care programs, which is a new vertical strategy for Biotricity. These developments mark a significant leap forward in our mission to deliver innovative, accessible, and high-quality cardiac care solutions." Q1-FY26 Financial Highlights Revenue increased 21% to $3.9 million, compared with $3.2 million in Q4 FY24 Gross margin was 80.5% for the three months ended June 30, 2025, as compared to 73.8% in the corresponding prior year quarter; this is the result of expansion in the recurring technology fee revenue base, efficiencies gained in using proprietary AI in operational automation, and improvement in monitoring and cloud cost structure. Net loss decreased to $0.75 million, or $0.03 per share, from a net loss of $6.9 million, or $0.49 per share, in Q1-FY25; this was an 80.6% improvement even after removing the effects of a $3 million one-time deemed dividend in the corresponding prior year period. Positive EBITDA of $333,337, first time in the Company's history; EBITDA increased by 118.7% compared to corresponding prior year quarter; this is the result of growth and operating efficiencies. Operating Highlights for Q1-FY26 and the Future Q1-FY26 recurring (TaaS) Technology Fees rose a robust 11.8% from the corresponding period of the prior year, to $3.4 million, which is also 7.9% increase from the immediately preceding three-month period. Company maintained its track record of strong customer retention, supported by the quality of customer and physician-friendly support services which emphasize the accuracy of our diagnostics and ease-of-use of our solution. Leveraging on its adept development of a range of state-of-the-art products to service a total addressable market of $35 billion. Working on achieving regulatory approval in internation markets, with a view to laying the foundation for distribution in those markets in the coming years, after successfully achieving approvals in Canada, Saudi Arabia and Argentina. Expansion of geographic footprint across 70% of the US, with penetration across thousands of physicians over hundreds of centers, including those acquired through relationships with strategic partners. Secured strategic alliances with three of the top GPOs representing 90% of all hospitals in the US. Full details of the Company's financial results will be filed with the SEC on Form 10-Q and available by visiting Financial Results and Business Update Conference Call Management will host a conference call on Thursday August 14, 2025 at 4:30 p.m. ET to discuss its financial results for fiscal first quarter of 2026 and provide a business update. Additional details are available under the Investor Relations section of the Company's website: Event: Biotricity First Quarter Fiscal 2026 Financial Results and Business Update CallDate: Thursday, August 14, 2025Time: 4:30pm ET (1:30pm PT) Toll Free: 1-877-269-7751 International: 1-201-389-0908 Webcast URL: Investors can begin accessing the webcast 15 minutes before the call, where an operator will register your name and organization. The call will be in listen-only mode. A replay of the call will be available approximately three hours after the live call via the Investors section of the Biotricity website at Toll Free Replay Number: 1-844-512-2921 International: 1-412-317-6671 Replay Access ID: 13755374Expiration: Thursday, August 28, 2025 at 11:59 PM ET About Biotricity Inc. Biotricity is reforming the healthcare market by bridging the gap in remote monitoring and chronic care management. Doctors and patients trust Biotricity's unparalleled standard for preventive & personal care, including diagnostic and post-diagnostic solutions for chronic conditions. The Company develops comprehensive remote health monitoring solutions for the medical and consumer markets. To learn more, visit Non-GAAP Measures Non-GAAP financial information presented may be determined or calculated differently by other companies and may not be directly comparable to that of other companies. It is management's intent to provide non-GAAP financial information to enhance the understanding of Biotricity's GAAP financial information, and it should be considered by the reader in addition to, but not instead of, the financial statements prepared in accordance with GAAP. We believe that providing these non-GAAP measures in addition to the GAAP measures allows management, investors and other users of our financial information to more fully and accurately assess business performance. Earnings before interest, tax, depreciation and amortization ('EBITDA') is one such measure: 3 months endedJune 30,2025 3 months endedJune 30,2024 $ $ Net loss attributable to common stockholders (754,293 ) (6,948,292 ) Add: Provision for income taxes - - Interest expense 850,254 768,673 Accretion and amortization expenses 153,572 1,144,728 Depreciation 1,488 1,488 Preferred stock dividends 82,316 3,253,772 EBITDA 333,337 (1,779,631 ) Weighted average number of common shares outstanding 26,284,734 14,169,441 Profit (Loss) per Share, Basic and Diluted 0.013 (0.126 ) Important Cautions Regarding Forward-Looking Statements Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words "may," "should," "would," "will," "could," "scheduled," "expect," "anticipate," "estimate," "believe," "intend," "seek," "project," or "goal" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements may include, without limitation, statements regarding (i) the plans, objectives and goals of management for future operations, including plans, objectives or goals relating to the design, development and commercialization of Bioflux or any of the Company's other proposed products or services, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company's future financial performance, (iv) the regulatory regime in which the Company operates or intends to operate and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain additional financing, the significant length of time and resources associated with the development of its products and related insufficient cash flows and resulting illiquidity, the Company's inability to expand the Company's business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release. Contacts Investor RelationsBiotricity Investor RelationsInvestors@ SOURCE: Biotricity Inc.
Yahoo
19-07-2025
- Business
- Yahoo
Biotricity Inc (BTCY) Q4 2025 Earnings Call Highlights: Revenue Growth and Strategic ...
Revenue (Q4 2025): $3.7 million, a 16.5% increase year-over-year. Revenue (Fiscal Year 2025): $13.8 million, up 14.3% from the prior year. Gross Profit (Q4 2025): $3 million, a 31% increase from the prior year period. Gross Margin (Q4 2025): 80.4%, an improvement of over 890 basis points from the prior year. Operating Expenses (Fiscal Year 2025): $13 million, a 24.5% decrease from the prior year. Net Loss (Fiscal Year 2025): $11.9 million, compared to $14.9 million in the prior year. Net Loss Per Share (Fiscal Year 2025): $0.555, compared to $1.66 in the prior year. Adjusted EBITDA (Q4 2025): Positive $438,000, corresponding to $0.017 per share. Adjusted EBITDA (Fiscal Year 2025): Loss of just under $1 million, improved from a loss of $7.8 million in fiscal '24. Warning! GuruFocus has detected 6 Warning Signs with BTCY. Release Date: July 18, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Biotricity Inc (BTCY) achieved a 16.5% year-over-year revenue increase in the fourth quarter, reaching $3.7 million. The company expanded its Cardiac AI cloud platform through strategic partnerships with Amazon AWS and Google's TensorFlow, enhancing diagnostic accuracy and patient outcomes. Biotricity Inc (BTCY) secured strategic alliances with three major group purchasing organizations, providing access to approximately 90% of U.S. hospitals. The company achieved positive adjusted EBITDA of $438,000 in the last quarter of fiscal 2025, indicating progress towards profitability. Biotricity Inc (BTCY) received regulatory approval in Saudi Arabia, aligning with its strategy to expand internationally and improve patient outcomes. Negative Points Biotricity Inc (BTCY) reported a net loss attributable to common stockholders of $11.9 million for the fiscal year ended March 31, 2025. The sales cycles for new partnerships and pilots with GPOs are lengthy, potentially delaying revenue realization. Despite improvements, the company still faces challenges in achieving profitability, with a net loss per share of $0.555 for the fiscal year. The company lacks in-house expertise to monetize its extensive data set, which could be a missed opportunity for additional revenue. Biotricity Inc (BTCY) anticipates that international market revenue contributions, such as from Saudi Arabia, may not significantly impact financials until 2026. Q & A Highlights Q: When can we expect greater acceleration in terms of revenue from your GPO relationships? A: Waqaas Al-Siddiq, CEO: The GPOs involve long sales cycles, often taking up to a year. We are currently engaging in pilots with large, multistate organizations. Revenue will start to trickle in as these pilots conclude and roll out over the next few quarters. Q: Which cost levers give you confidence that margins can stay above 80% in 2026? A: Waqaas Al-Siddiq, CEO: Our technology, particularly data analysis and device output, provides high margins. We've achieved economies of scale, reducing costs for each new device added to our platform, which helps maintain high margins. Q: Can the data set of over 1 trillion heartbeats be monetized beyond improving clinical algorithms? A: Waqaas Al-Siddiq, CEO: Yes, there is potential to monetize this data, especially given the focus on cardiac health. While we currently lack the in-house skill set to package and sell this data, we plan to invest in this area as we reach profitability. Q: What are your efforts in pursuing FDA clearance for your AI clinical model? A: Waqaas Al-Siddiq, CEO: We are in the process of analyzing data and bringing in experts for secondary input. We plan to present this to the FDA in a pre-submission meeting to ensure our approach aligns with their requirements. This is a complex process, but we are targeting significant opportunities. Q: How do you see the Saudi Arabian market impacting revenue for the rest of 2025 and next year? A: Waqaas Al-Siddiq, CEO: We expect significant impact in 2026. We aim for 20-30% of our business to be international in the coming years. For next year, we anticipate $0.5 million to $1 million in added revenue from international distribution partnerships. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error al recuperar los datos Inicia sesión para acceder a tu cartera de valores Error al recuperar los datos Error al recuperar los datos Error al recuperar los datos Error al recuperar los datos
Globe and Mail
17-07-2025
- Business
- Globe and Mail
Biotricity Delivers Strong Fiscal Year 2025 Results with Revenue Growth, Continued Margin Improvement, and Reduced Operating Expenses, Putting Profitability within Reach
FY25 revenue up 14.3% YOY FY25 margins improvement of 8.9% to 76.6%, from 69.3% in the prior year; Q4-FY25 margins improved to 80.4% as margin expansion forecasted to continue FY25 operating expenses lower by 24.5% YOY Negative EBITDA reduced by $5.7 million to $3.2 million – an improvement of 63.9% Positive Adjusted EBITDA of $438,260 in the fourth quarter of FY25 – first time in Company's history, highlighting Company's ability to achieve breakeven and EBITDA positive in the early part of its FY26 REDWOOD CITY, CA, July 17, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY) ("Biotricity" or the "Company"), a Technology-as-a-Service (TaaS) company that offers innovative diagnostic, chronic disease, and lifestyle management solutions for healthcare providers and consumers, today announced its financial results for the fourth quarter and fiscal year ended March 31, 2025. Dr. Waqaas Al-Siddiq, Biotricity Founder and CEO, said, "Fiscal 2025 has been another year of massive transformation for Biotricity. We've further utilized workflow automation, AI, and continued technological enhancements to drive substantial improvements in operational expenses, margin expansion, and revenue growth. This year, we demonstrated our ability to scale efficiently while maintaining high-quality service, bringing us to the doorstep of EBITDA breakeven and long-term profitability. The expansion of our Cardiac AI Cloud platform, supported by strategic partnerships with other industry leaders, showcases our commitment to revolutionizing medical diagnostics, chronic care management, and consumer healthcare. Leveraging over a trillion beats of anonymized data, our AI-driven platform is set to enhance clinic profitability and growth, paving the way for transformative advancements in diagnostic accuracy and patient outcomes. Importantly, we remain on track to pursue FDA clearance for our groundbreaking AI clinical model in the coming months. Collaborative partnerships established during fiscal 2025 and 2026 have positioned us to capitalize on expansive market channels, providing access to approximately 90% of all hospitals in America. Biotricity has also forged a strategic partnership focused on payor contracts for value based and managed care programs, both of which are new verticals for the Company. These developments underscore our dedication to advancing innovative, accessible, and high-quality cardiac care solutions." FY25 Financial Highlights Revenue increased 14.3% to $13.8 million compared with $12.1 million in FY24 Gross margin was 76.6% for the fiscal year ended March 31, 2025, as compared to 69.3% in FY24; this was the result of expansion in recurring technology fee revenue base, efficiencies gained in using proprietary AI in operational automation, and improvement in monitoring cost structure. Net loss decreased 20% YOY to $11.9 million, or $0.56 per share, from a net loss of $14.9 million, or $1.66 per share, in FY24 Q4-FY25 Financial Highlights Revenue increased 16.5% to $3.7 million compared with $3.5 million in Q4 FY24 Gross margin was 80.4% for the three months ended March 31, 2025, as compared to 71.5% in the corresponding prior year quarter Net loss decreased 54% YOY to $2 million, or $0.08 per share, from a net loss of $4.4 million, or $0.47 per share, in Q4-FY24 Operating Highlights for FY25 FY25 recurring (TaaS) Technology Fees rose a robust 12% YOY to $12.6 million, representing over 10.5 times Device Sales revenue Company continues to maintain an impressive track record of customer retention, driven by high-quality customer and provider friendly support services, emphasis on accurate diagnostics, and user-friendly solutions. Developed a range of state-of-the-art products to service a total addressable market of $35 billion. Secured strategic alliances with three of the top GPOs representing 90% of all hospitals in the US Arrived at positive cash flows by growing subscription-based revenues, improving margins, and leveraging automation and experience to increase efficiencies of SG&A. Full details of the Company's financial results will be filed with the SEC on Form 10-K and available by visiting Financial Results and Business Update Conference Call Management will host a conference call on Friday July 18, 2025 at 4:45 p.m. ET to discuss its financial results for fiscal year 2025 and provide a business update. Additional details are available under the Investor Relations section of the Company's website: Event: Biotricity Fourth Quarter and FY 2025 Financial Results and Business Update Call Date: Friday, July 18, 2025 Time: 4:45pm ET (1:45pm PT) Toll Free: 1-877-269-7751 International: 1-201-389-0908 Webcast URL: Investors can begin accessing the webcast 15 minutes before the call, where an operator will register your name and organization. The call will be in listen-only mode. A replay of the call will be available approximately three hours after the live call via the Investors section of the Biotricity website at Toll Free Replay Number: 1-844-512-2921 International: 1-412-317-6671 Replay Access ID: 13754989 Expiration: Friday, August 1, 2025 at 11:59 PM ET About Biotricity Inc. Biotricity is reforming the healthcare market by bridging the gap in remote monitoring and chronic care management. Doctors and patients trust Biotricity's unparalleled standard for preventive & personal care, including diagnostic and post-diagnostic solutions for chronic conditions. The Company develops comprehensive remote health monitoring solutions for the medical and consumer markets. To learn more, visit Non-GAAP Measures Non-GAAP financial information presented may be determined or calculated differently by other companies and may not be directly comparable to that of other companies. It is management's intent to provide non-GAAP financial information to enhance the understanding of Biotricity's GAAP financial information, and it should be considered by the reader in addition to, but not instead of, the financial statements prepared in accordance with GAAP. We believe that providing these non-GAAP measures in addition to the GAAP measures allows management, investors and other users of our financial information to more fully and accurately assess business performance. Year ended March 31, 2025 Year ended March 31, 2024 3 months ended March 31, 2025 3 months ended March 31, 2024 $ $ $ $ Net loss attributable to common stockholders (11,942,000) (14,928,960) (2,022,133) (4,400,104) Add: Provision for income taxes - - - - Interest expense 3,262,038 3,018,803 891,752 814,943 Accretion and amortization expenses 1,945,769 2,178,873 165,560 598,063 Preferred stock dividends 3,520,821 834,677 86,396 217,634 EBITDA (3,213,372) (8,896,607) (878,425) (2,769,464) Add (Less) Share based compensation (1) 1,420,121 1,025,930 1,247,319 481,275 Other (income)/loss (2) 78,569 102,607 (49,405) (16,334) Gain (loss) upon convertible promissory notes conversion and redemption (2) 141267 (18,539) (8,391) (3,259) Fair value change on derivative liabilities (2) 595,442 (9,777) 127,162 (253,791) Adjusted EBITDA (977,973) (7,796,386) 438,260 (2,561,573) Weighted average number of common shares outstanding 21,524,884 8,991,766 21,524,884 9,441,667 Adjusted Loss per Share, Basic and Diluted (0.045) (0.867) 0.017 (0.271) (1) Share based compensation is a non-cash item (2) These items relate to financing transactions and do not reflect the Company's core operating activities Important Cautions Regarding Forward-Looking Statements Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words "may," "should," "would," "will," "could," "scheduled," "expect," "anticipate," "estimate," "believe," "intend," "seek," "project," or "goal" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements may include, without limitation, statements regarding (i) the plans, objectives and goals of management for future operations, including plans, objectives or goals relating to the design, development and commercialization of Bioflux or any of the Company's other proposed products or services, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company's future financial performance, (iv) the regulatory regime in which the Company operates or intends to operate and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain additional financing, the significant length of time and resources associated with the development of its products and related insufficient cash flows and resulting illiquidity, the Company's inability to expand the Company's business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release. Contacts
Yahoo
07-07-2025
- Business
- Yahoo
Rogue Funds' New Holding: Biotricity (BTCY)
Rogue Funds, an investment management company, released its first quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund depreciated 12.4% net of fees in the quarter. The firm anticipates significant volatility in the near future. Because of the Fund's concentration, significant declines as well as significant rises in the total returns throughout the course of the year are not unusual. In addition, you can check the fund's top 5 holdings to determine its best picks for 2025. In its first quarter 2025 investor letter, Rogue Funds highlighted stocks such as Biotricity, Inc. (OTC:BTCY). Biotricity, Inc. (OTC:BTCY) is a medical technology company. The one-month return of Biotricity, Inc. (OTC:BTCY) was -19.98%, and its shares lost 45.13% of their value over the last 52 weeks. On July 3, 2025, Biotricity, Inc. (OTC:BTCY) stock closed at $0.42 per share, with a market capitalization of $10.465 million. Rogue Funds stated the following regarding Biotricity, Inc. (OTC:BTCY) in its first quarter 2025 investor letter: "Biotricity, Inc. (OTC:BTCY): This isn't a particularly new holding for the company, but it has been one that we have slowly built a position in since August/September. The company manufactures and sells a three-lead heart monitor and supplies technology that helps in predictability of heart related issues. It can be worn for 30 days and they maintain a 99% retention rate. The device is the best in its class, and they have grown at a solid 25%+ clip to $13mm in revenue that is likely to increase in the near future. In the fall of 2023/early 2024 they began switching their company to focus on providing AI benefits for their device and allowing for a TAAS/SAAS conversion which slowed down sales initially but has led to a large amount of pilot studies taking place. This SAAS conversion has allowed the gross margin to expand significantly, which I expect to continue through the year. A medical professional wearing a lab coat using an advanced ECG device. Biotricity, Inc. (OTC:BTCY) is not on our list of 30 Most Popular Stocks Among Hedge Funds. While we acknowledge the potential of Biotricity, Inc. (OTC:BTCY) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the undervalued AI stock set for massive gains. In addition, please check out our hedge fund investor letters Q1 2025 page for more investor letters from hedge funds and other leading investors. While we acknowledge the potential of BTCY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
17-06-2025
- Business
- Yahoo
Purpose Investments Inc. Announces June 2025 Distributions
TORONTO, June 17, 2025 (GLOBE NEWSWIRE) -- Purpose Investments Inc. ('Purpose') is pleased to announce distributions for the month of June 2025 for its open-end exchange traded funds and closed-end funds ('the Funds'). The ex-distribution date for all Open-End Funds is June 26, 2025. The ex-distribution date for all closed-end funds is June 30, 2025. Open-End Funds Ticker Symbol Distribution per share/unit Record Date Payable Date Distribution Frequency Apple (AAPL) Yield Shares Purpose ETF - ETF Units APLY $0.1667 06/26/2025 07/03/2025 Monthly Purpose Canadian Financial Income Fund - ETF Series BNC $0.1225¹ 06/26/2025 07/03/2025 Monthly Purpose Global Bond Fund - ETF Units BND $0.0866 06/26/2025 07/03/2025 Monthly Berkshire Hathaway (BRK) Yield Shares Purpose ETF - ETF Units BRKY $0.1000 06/26/2025 07/03/2025 Monthly Purpose Bitcoin Yield ETF - ETF Units BTCY $0.0850 06/26/2025 07/03/2025 Monthly Purpose Bitcoin Yield ETF - ETF Non-Currency Hedged Units BTCY.B $0.0970 06/26/2025 07/03/2025 Monthly Purpose Bitcoin Yield ETF - ETF USD Units BTCY.U US $0.0815 06/26/2025 07/03/2025 Monthly Purpose Credit Opportunities Fund - ETF Units CROP $0.0875 06/26/2025 07/03/2025 Monthly Purpose Credit Opportunities Fund - ETF USD Units CROP.U US $0.0975 06/26/2025 07/03/2025 Monthly Purpose Ether Yield - ETF Units ETHY $0.0405 06/26/2025 07/03/2025 Monthly Purpose Ether Yield ETF - ETF Non-Currency Hedged Units ETHY.B $0.0500 06/26/2025 07/03/2025 Monthly Purpose Ether Yield ETF - ETF Units Non-Currency Hedged USD Units ETHY.U US $0.0395 06/26/2025 07/03/2025 Monthly Purpose Global Flexible Credit Fund - ETF Units FLX $0.0461 06/26/2025 07/03/2025 Monthly Purpose Global Flexible Credit Fund - Non-Currency Hedged - ETF Units FLX.B $0.0551 06/26/2025 07/03/2025 Monthly Purpose Global Flexible Credit Fund - Non-Currency Hedged USD - ETF Units FLX.U US $0.0385 06/26/2025 07/03/2025 Monthly Purpose Global Bond Class - ETF Units IGB $0.0860¹ 06/26/2025 07/03/2025 Monthly Microsoft (MSFT) Yield Shares Purpose ETF - ETF units MSFY $0.1300 06/26/2025 07/03/2025 Monthly Purpose Active Balanced Fund - ETF Units PABF $0.1650 06/26/2025 07/03/2025 Quarterly Purpose Active Conservative Fund - ETF Units PACF $0.1900 06/26/2025 07/03/2025 Quarterly Purpose Active Growth Fund - ETF Units PAGF $0.1550 06/26/2025 07/03/2025 Quarterly Purpose Enhanced Premium Yield Fund - ETF Series PAYF $0.1375¹ 06/26/2025 07/03/2025 Monthly Purpose Total Return Bond Fund - ETF Series PBD $0.0590¹ 06/26/2025 07/03/2025 Monthly Purpose Core Dividend Fund - ETF Series PDF $0.1050¹ 06/26/2025 07/03/2025 Monthly Purpose Enhanced Dividend Fund - ETF Series PDIV $0.0950¹ 06/26/2025 07/03/2025 Monthly Purpose Real Estate Income Fund - ETF Series PHR $0.0720¹ 06/26/2025 07/03/2025 Monthly Purpose International Tactical Hedged Equity Fund - ETF Series PHW $0.1500 06/26/2025 07/03/2025 Quarterly Purpose International Dividend Fund - ETF Series PID $0.0780 06/26/2025 07/03/2025 Monthly Purpose Monthly Income Fund - ETF Series PIN $0.0830¹ 06/26/2025 07/03/2025 Monthly Purpose Multi-Asset Income Fund - ETF Units PINC $0.0840 06/26/2025 07/03/2025 Monthly Purpose Diversified Real Asset Fund - ETF Series PRA $0.2100 06/26/2025 07/03/2025 Quarterly Purpose Conservative Income Fund - ETF Series PRP $0.0600¹ 06/26/2025 07/03/2025 Monthly Purpose Premium Yield Fund - ETF Series PYF $0.1100¹ 06/26/2025 07/03/2025 Monthly Purpose Premium Yield Fund Non-Currency Hedged - ETF Series PYF.B $0.1230¹ 06/26/2025 07/03/2025 Monthly Purpose Premium Yield Fund Non-Currency Hedged - ETF USD Series PYF.U US $0.1200¹ 06/26/2025 07/03/2025 Monthly Purpose Core Equity Income Fund - ETF Series RDE $0.0875¹ 06/26/2025 07/03/2025 Monthly Purpose Emerging Markets Dividend Fund - ETF Units REM $0.0950 06/26/2025 07/03/2025 Monthly Purpose Canadian Preferred Share Fund - ETF Units RPS $0.0950 06/26/2025 07/03/2025 Monthly Purpose US Preferred Share Fund - ETF Series RPU $0.0940 06/26/2025 07/03/2025 Monthly Purpose US Preferred Share Fund Non-Currency Hedged - ETF Units2 RPU.B / RPU.U $0.0940 06/26/2025 07/03/2025 Monthly Purpose Strategic Yield Fund - ETF Units SYLD $0.0970 06/26/2025 07/03/2025 Monthly AMD (AMD) Yield Shares Purpose ETF - ETF Series YAMD $0.2500 06/26/2025 07/03/2025 Monthly Amazon (AMZN) Yield Shares Purpose ETF- ETF Units YAMZ $0.4000 06/26/2025 07/03/2025 Monthly Broadcom (AVGO) Yield Shares Purpose ETF - ETF Series YAVG $0.1800 06/26/2025 07/03/2025 Monthly Coinbase (COIN) Yield Shares Purpose ETF - ETF Series YCON $0.3000 06/26/2025 07/03/2025 Monthly Costco (COST) Yield Shares Purpose ETF - ETF Series YCST $0.1200 06/26/2025 07/03/2025 Monthly Alphabet (GOOGL) Yield Shares Purpose ETF - ETF Units YGOG $0.2500 06/26/2025 07/03/2025 Monthly Tech Innovators Yield Shares Purpose ETF - ETF Series YMAG $0.2000 06/26/2025 07/03/2025 Monthly META (META) Yield Shares Purpose ETF - ETF Series YMET $0.2400 06/26/2025 07/03/2025 Monthly Netflix (NFLX) Yield Shares Purpose ETF - ETF Series YNET $0.1500 06/26/2025 07/03/2025 Monthly NVIDIA (NVDA) Yield Shares Purpose ETF - ETF Units YNVD $0.7500 06/26/2025 07/03/2025 Monthly Palantir (PLTR) Yield Shares Purpose ETF - ETF Series YPLT $0.2500 06/26/2025 07/03/2025 Monthly Tesla (TSLA) Yield Shares Purpose ETF - ETF Units YTSL $0.5500 06/26/2025 07/03/2025 Monthly UnitedHealth Group (UHN) Yield Shares Purpose ETF - ETF Series YUNH $0.1100 06/26/2025 07/03/2025 Monthly Closed-End Funds Ticker Symbol Distribution per share/unit Record Date Payable Date Distribution Frequency Big Banc Split Corp, Class A BNK $0.1200¹ 06/30/2025 07/14/2025 Monthly Big Banc Split Corp - Preferred Shares $0.0700¹ 06/30/2025 07/14/2025 Monthly Estimated June 2025 Distributions for Purpose USD Cash Management Fund, Purpose Cash Management Fund, Purpose High Interest Savings Fund, and Purpose US Cash Fund The June 2025 distribution rates for Purpose USD Cash Management Fund, Purpose Cash Management Fund, Purpose High Interest Savings Fund, and Purpose US Cash Fund are estimated to be as follows: Fund Name Ticker Symbol Estimated Distribution per unit Record Date Payable Date Distribution Frequency Purpose USD Cash Management Fund - ETF Units MNU.U US $0.3405 06/26/2025 07/03/2025 Monthly Purpose Cash Management Fund - ETF Units MNY $0.2175 06/26/2025 07/03/2025 Monthly Purpose High Interest Savings Fund - ETF Units PSA $0.1030 06/26/2025 07/03/2025 Monthly Purpose US Cash Fund - ETF Units PSU.U US $0.3375 06/26/2025 07/03/2025 Monthly Purpose expects to issue a press release on or about June 25, 2025, which will provide the final distribution rate for Purpose USD Cash Management Fund, Purpose Cash Management Fund, Purpose High Interest Savings Fund, and Purpose US Cash Fund. The ex-distribution date will be June 26, 2025. Dividend is designated as an 'eligible' Canadian dividend for purposes of the Income Tax Act (Canada) and any similar provincial and territorial legislation. Purpose US Preferred Share Fund Non-Currency Hedged – ETF Units have both a CAD and USD purchase option. Distribution per unit is declared in CAD, however, the USD purchase option (RPU.U) distribution will be made in the USD equivalent. Conversion into USD will use the end-of-day foreign exchange rate prevailing on the ex-distribution date. About Purpose Investments Inc. Purpose Investments is an asset management company with more than $21 billion in assets under management. Purpose Investments has an unrelenting focus on client-centric innovation and offers a range of managed and quantitative investment products. Purpose Investments is led by well-known entrepreneur Som Seif and is a division of Purpose Unlimited, an independent technology-driven financial services company. For further information please contact:Keera Commissions, trailing commissions, management fees and expenses all may be associated with investment fund investments. Please read the prospectus and other disclosure documents before investing. Investment funds are not covered by the Canada Deposit Insurance Corporation or any other government deposit insurer. There can be no assurance that the full amount of your investment in a fund will be returned to you. If the securities are purchased or sold on a stock exchange, you may pay more or receive less than the current net asset value. Investment funds are not guaranteed, their values change frequently and past performance may not be al recuperar los datos Inicia sesión para acceder a tu cartera de valores Error al recuperar los datos Error al recuperar los datos Error al recuperar los datos Error al recuperar los datos
